VH4004280 (VH-280)

Evidence outlook · lead readout

NCT06039579 · HIV Infections

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT06039579: This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.